Preoperative Paravertebral Block in Cancer Surgery of the Lung (ParaSOL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04209868|
Recruitment Status : Recruiting
First Posted : December 24, 2019
Last Update Posted : June 4, 2021
|Condition or disease||Intervention/treatment||Phase|
|Thoracic Neoplasm Chronic Pain Post-Procedural Acute Post-thoracotomy Pain Anesthesia, Local||Drug: Levo-Bupivacaine Hydrochloride (HCl) 0.25 % in 20mL Injection Drug: 0.9% Sodium Chloride 20mL Injection||Phase 2 Phase 3|
In the UK, there has been an increase in lung cancer operations, especially in high risk and elderly patients, improving survival from 10.6% in 2008 to 15.1% in 2013. Lung cancer surgery is associated with severe acute pain, a high incidence of respiratory complications and chronic post-surgical pain. Severe acute postoperative pain is a strong predictor of CPSP. The improvement of perioperative outcomes in elderly patients, the benefits of regional anaesthesia and reduction of chronic pain are investigative priorities of the Anaesthesia and Perioperative Care Setting Partnership.
Enhanced recovery strategies include video-assisted thoracoscopic surgery (VATS), a minimally invasive alternative to open thoracotomy, which may be associated with less postoperative pain. Regional anaesthesia, by thoracic epidural analgesia (TEA) or PVB, is superior to systemic opioids in reducing acute pain after thoracotomy surgery.
Preemptive analgesia describes the aim of minimizing central spinal pain transmission by noxious stimuli arising from events at surgery, by administering an analgesic technique prior to surgical incision. Regional blockade affects central sensitization, allowing analgesia to outlast the pharmacological sensory blockade.
Compared to TEA initiated after surgery, acute pain severity is reduced by preemptive TEA. There are conflicting reports on the benefit of preemptive analgesia in other types of surgery, but TEA and PVB may prevent CPSP in thoracotomy and breast surgery. Some small studies have shown that pre-PVB reduces acute postoperative pain.
Paravertebral blockade is known to be as effective as TEA for acute postoperative analgesia following thoracic surgery, whilst having a lower incidence of pulmonary complications, hypotension and nausea. It is conventional practice in many centres for the surgical administration and placement of a catheter at the end of surgery for postoperative LA infusion (post-PVB) as the sole method of regional analgesia. Preoperative PVB is less common: anaesthetists may use a landmark technique, single or multiple injections and different volumes/strengths of LA.
Ultrasound guidance for pre-PVB injection increases accuracy. In an audit using this technique with post-PVB compared to post-PVB only, the investigators demonstrated reduced pain numerical rating scale (NRS) scores in elective VATS patients, (mean NRS at 24h 2.5 vs 4.5), and a reduction in the proportion of patients who experienced moderate-to-severe pain of NRS≥ 3 from 83% to 50% at 24h.
The investigators therefore aim to evaluate the contribution of ultrasound-guided pre-PVB, administered in addition to the post-PVB LA infusion, in reducing the severity of acute postoperative pain, perioperative opioid requirement, development of CPSP, and improving patient outcome in lung cancer patients undergoing VATS.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
The study will be conducted at Guy's Hospital, London, United Kingdom (UK), a large tertiary thoracic centre for London, Sussex, Kent and Berkshire. In 2015, 459 lung cancer resection operations were performed; 8% of all lung cancer resections in England.
Criteria for discontinuation/withdrawal or modifying allocated treatment:
Patient recruitment Eligible patients will be identified in the catchment outpatient clinics 4-6 weeks before surgery. The participant information sheet (PIS) will be introduced in the standard surgical booklet given by the surgeon. At the preoperative assessment clinic 2-3 weeks before surgery, a face-to-face discussion with the research nurse will support the PIS; the opportunity to ask any questions and contact a PPI (Patient and Public Involvement) representative and will be given. Written informed consent will be obtained.
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
Participants will be randomised on the day of surgery to the 'pre-PVB LA' or 'pre-PVB saline' arm, by a study investigator, with a 1:1 randomisation ratio using 'Sealed Envelope' (www.sealedenvelope.com) online software. Each subject will receive a unique randomization code in an envelope that will only be opened during the preparation of the pre-PVB injectate.
A non-blinded research nurse, will prepare the pre-PVB injectate in a standard syringe according to the allocation, labelled by participant number, in a theatre location concealed from the operating room and staff.
The anaesthetist, the surgeon and theatre team, recovery staff, and the researchers performing all the outcome assessments will be separate and blinded to the group allocation. The PVB catheter will be taped as normal before connecting the post-PVB LA infusion pump.
We have elected to perform an interventional placebo intervention as opposed to a sham control to minimize observer bias.
|Official Title:||Preoperative Paravertebral Block in Cancer Surgery of the Lung: ParaSOL a Prospective Randomized Controlled Clinical Trial|
|Actual Study Start Date :||February 1, 2019|
|Estimated Primary Completion Date :||September 2021|
|Estimated Study Completion Date :||May 31, 2022|
Placebo Comparator: Pre-PVB with saline
Placebo (20ml Saline) pre-PVB performed post-induction and pre-incision.
Drug: 0.9% Sodium Chloride 20mL Injection
As per arm description
Experimental: Pre-PVB with 0.25% Levo-bupivacaine
20ml 0.25% Levo-bupivacaine pre-PVB performed post-induction and pre-incision.
Drug: Levo-Bupivacaine Hydrochloride (HCl) 0.25 % in 20mL Injection
As per arm description
- Moderate-to-severe pain Numerical Rating Scale (NRS) >/=3 [ Time Frame: 1 day ]The proportion of patients with clinical relevant moderate-to-severe pain (NRS>/=3) related to the surgical site at rest at 24 hours.
- Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing. [ Time Frame: 1 hour ]Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing, preoperatively, and after arrival in recovery at 1, 6, 24 and 48 hours
- Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing. [ Time Frame: 6 hours ]Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing, preoperatively, and after arrival in recovery at 1, 6, 24 and 48 hours
- Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing. [ Time Frame: 24 hours ]Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing, preoperatively, and after arrival in recovery at 1, 6, 24 and 48 hours
- Acute postoperative pain related to the surgical site as measured by a numerical rating scale (NRS) at rest and on coughing. [ Time Frame: 48 hours ]
- Cumulative morphine requirement [ Time Frame: 48 hours ]Cumulative morphine requirement over 48 hours post arrival in recovery
- Time to first mobilization [ Time Frame: 3 days ]Time to first mobilization (walking 50 metres without the aid of another person), measured at baseline pre-operatively and postoperatively on daily assessment.
- Incidence of in-hospital complications [ Time Frame: 3 days ]Incidence of in-hospital complications (Atrial Fibrillation (AF), Myocardial Infarction (MI), unplanned ICU admission) and respiratory complications, as defined by the Melbourne Group Scale.
- Length of hospital stay [ Time Frame: 3 days ]Length of hospital stay (in days)
- Quality of Life (QoL) score [ Time Frame: Pre-operative and at 3 and 6 months post-operatively ]Quality of Life (QoL) score as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) version 3
- Presence of chronic post-surgical pain [ Time Frame: Measured at 3 and 6 months post-operatively ]Presence of chronic post-surgical pain (CPSP) (binary yes/no) fulfilling CPSP criteria
- Presence of chronic post-surgical pain [ Time Frame: Measured at 3 and 6 months post-operatively ]Presence of chronic post-surgical pain assessed by the Brief Pain Inventory Short Form (BPI-SF)
- Presence of chronic post-surgical pain [ Time Frame: Measured at 3 and 6 months post-operatively ]Presence of chronic post-surgical pain assessed by as defined by the Melbourne Group Scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04209868
|Contact: Cheng Ong, MBBS||+44 firstname.lastname@example.org|
|Contact: Craig R Johnstone, MBChB||+44 email@example.com|
|Guy's Hospital, Great Maze Pond||Recruiting|
|London, United Kingdom, SE1 9RT|
|Contact: Gill Arbane 0207 188 8070 firstname.lastname@example.org|
|Principal Investigator: Cheng Ong, MBBS|
|Sub-Investigator: Craig R Johnstone, MBChB|
|Study Chair:||Cheng Ong||Guys & St Thmas' NHS Foundation Trust|